Takeda's Kazano Supplement Application Approved by FDA
The FDA has approved the supplemental application for Kazano (Alogliptin Benzoate and Metformin Hydrochloride) submitted by Takeda Pharmaceuticals USA.
Asset / Drug
Drug and asset intelligence for Kazano with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.